Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “HER2-positive Carcinoma of Breast”

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 0 results

Large-scale testing (Phase 3)Ended earlyNCT05128773
What this trial is testing

Study of Amcenestrant (SAR439859) Versus Tamoxifen for Patients With Hormone Receptor-positive (HR+) Early Breast Cancer, Who Have Discontinued Adjuvant Aromatase Inhibitor Therapy Due to Treatment-related Toxicity

Who this might be right for
Breast Cancer
Sanofi 3
Early research (Phase 1)Study completedNCT02088684
What this trial is testing

Study of LEE011 With Fulvestrant and BYL719 or BKM120 in Advanced Breast Cancer

Who this might be right for
Breast Cancer
Novartis Pharmaceuticals 70
Testing effectiveness (Phase 2)Ended earlyNCT00597597
What this trial is testing

Phase II Open-Label Trial of Tarceva in Women With Metastatic, Hormone- and HER2-Negative Breast Cancer

Who this might be right for
Metastatic Breast Cancer
Rush University Medical Center 11
Not applicableLooking for participantsNCT06171360
What this trial is testing

The Gut Microbiome in Hormone Receptor-positive HER2-negative Breast Cancer Treated With CDK4/6 Inhibitors

Who this might be right for
Breast Cancer
Cliniques universitaires Saint-Luc- Université Catholique de Louvain 100
Testing effectiveness (Phase 2)Looking for participantsNCT05020860
What this trial is testing

Correlation of Clinical Response to Pathologic Response in Patients With Early Breast Cancer

Who this might be right for
Breast CancerBreast NeoplasmBreast Cancer Female+8 more
Baylor Breast Care Center 185
Testing effectiveness (Phase 2)Ended earlyNCT00759642
What this trial is testing

Lapatinib in Women With Metastatic Breast Cancer Who Have Failed Prior Antihormone Therapy

Who this might be right for
Metastatic Breast Cancer
University of Kansas Medical Center 33
Testing effectiveness (Phase 2)Study completedNCT00238290
What this trial is testing

Trastuzumab and Letrozole in Treating Postmenopausal Women With Progressive Advanced Breast Cancer

Who this might be right for
Breast Cancer
Swiss Cancer Institute 13
Early research (Phase 1)Study completedNCT03319459
What this trial is testing

FATE-NK100 as Monotherapy and in Combination With Monoclonal Antibody in Subjects With Advanced Solid Tumors

Who this might be right for
HER2 Positive Gastric CancerColorectal CancerHead and Neck Squamous Cell Carcinoma+8 more
Fate Therapeutics 44
Not applicableApproved For MarketingNCT04220203
What this trial is testing

Treatment Protocol of Tucatinib With Capecitabine and Trastuzumab in Patients With Unresectable Previously Treated HER2+ Breast Cancer

Who this might be right for
HER2-positive Breast Cancer
Seagen, a wholly owned subsidiary of Pfizer
Large-scale testing (Phase 3)Study completedNCT02278120
What this trial is testing

Study of Efficacy and Safety in Premenopausal Women With Hormone Receptor Positive, HER2-negative Advanced Breast Cancer

Who this might be right for
Advanced Metastatic Breast Cancer
Novartis Pharmaceuticals 672
Early research (Phase 1)UnknownNCT04660929
What this trial is testing

CAR-macrophages for the Treatment of HER2 Overexpressing Solid Tumors

Who this might be right for
HER2-positiveAdenocarcinomaBile Duct Cancer+28 more
Carisma Therapeutics Inc 48
Testing effectiveness (Phase 2)Looking for participantsNCT04985266
What this trial is testing

A Trial of Early Detection of Molecular Relapse With Circulating Tumour DNA Tracking and Treatment With Palbociclib Plus Fulvestrant Versus Standard Endocrine Therapy in Patients With ER Positive HER2 Negative Breast Cancer

Who this might be right for
ER+ Breast CancerHER2-negative Breast Cancer
Royal Marsden NHS Foundation Trust 1,100
Large-scale testing (Phase 3)Study completedNCT01985724
What this trial is testing

Sequential Administration of FE75C and Docetaxel Versus Docetaxel/Cyclophosphamide in HER-2 Negative, Node Positive Breast Cancer

Who this might be right for
Breast Cancer
Hellenic Oncology Research Group 650
Testing effectiveness (Phase 2)UnknownNCT03497702
What this trial is testing

Neo-adjuvant Chemotherapy With Letrozole in Patients With Estrogen Receptor Positive/HER-2 Negative Breast Cancer

Who this might be right for
Breast CancerInvasive Breast Cancer
National Cancer Center, Korea 114
Testing effectiveness (Phase 2)Study completedNCT01138046
What this trial is testing

Phase I/II Study of Lapatinib in Combination With Paclitaxel as 1L Chemotherapy for ErbB2-positive MBC

Who this might be right for
Neoplasms, Breast
GlaxoSmithKline 12
Large-scale testing (Phase 3)Study completedNCT00309556
What this trial is testing

Randomized Neoadjuvant Study of Epirubicin and Docetaxel With/Without Capecitabine in Early Breast Cancer

Who this might be right for
Breast Cancer
Austrian Breast & Colorectal Cancer Study Group 536
Early research (Phase 1)Study completedNCT03619681
What this trial is testing

Trial of KN026 in Patients With HER2-positive Advanced Malignant Breast Cancer and Gastric Cancer

Who this might be right for
Breast CancerGastric Cancer
Jiangsu Alphamab Biopharmaceuticals Co., Ltd 63
Not applicableStudy completedNCT06307457
What this trial is testing

HR+/HER2- Metastatic Breast Cancer Patients Treated With Palbociclib Together With an Aromatase Inhibitor From 2017 to 2023 in Denmark.

Who this might be right for
Breast Cancer
Pfizer 604
Not applicableStudy completedNCT04857619
What this trial is testing

Study to Describe the Real-world Treatment Patterns and Associated Outcomes in Patients With HER2-positive Unresectable or Metastatic Breast Cancer

Who this might be right for
Metastatic Breast Cancer
AstraZeneca 763
Not applicableStudy completedNCT07052734
What this trial is testing

Miti-gene Recurrence Score in HR+/HER2- Chinese Breast Cancer Patients

Who this might be right for
Breast Cancer
Sun Yat-sen University 2,843
Next Page